Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tucker, Douglass W. | - |
dc.contributor.author | Getchell, Christopher R. | - |
dc.contributor.author | McCarthy, Eric T. | - |
dc.contributor.author | Ohman, Anders W. | - |
dc.contributor.author | Sasamoto, Naoko | - |
dc.contributor.author | Xu, Shuyun | - |
dc.contributor.author | Ko, Joo Yeon | - |
dc.contributor.author | Gupta, Mamta | - |
dc.contributor.author | Shafrir, Amy | - |
dc.contributor.author | Medina, Jamie E. | - |
dc.contributor.author | Lee, Jonathan J. | - |
dc.contributor.author | MacDonald, Lauren A. | - |
dc.contributor.author | Malik, Ammara | - |
dc.contributor.author | Hasselblatt, Kathleen T. | - |
dc.contributor.author | Li, Wenjing | - |
dc.contributor.author | Zhang, Hong | - |
dc.contributor.author | Kaplan, Samuel J. | - |
dc.contributor.author | Murphy, George F. | - |
dc.contributor.author | Hirsch, Michelle S. | - |
dc.contributor.author | Liu, Joyce F. | - |
dc.contributor.author | Matulonis, Ursula A. | - |
dc.contributor.author | Terry, Kathryn L. | - |
dc.contributor.author | Lian, Christine G. | - |
dc.contributor.author | Dinulescu, Daniela M. | - |
dc.date.accessioned | 2022-07-12T09:47:46Z | - |
dc.date.available | 2022-07-12T09:47:46Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2018-03 | - |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/150473 | - |
dc.description.abstract | Purpose: A major challenge in platinum-based cancer therapy is the clinical management of chemoresistant tumors, which have a largely unknown pathogenesis at the level of epigenetic regulation. Experimental Design: We evaluated the potential of using global loss of 5-hydroxymethylcytosine (5-hmC) levels as a novel diagnostic and prognostic epigenetic marker to better assess platinum-based chemotherapy response and clinical outcome in high-grade serous tumors (HGSOC), the most common and deadliest subtype of ovarian cancer. Furthermore, we identified a targetable pathway to reverse these epigenetic changes, both genetically and pharmacologically. Results: This study shows that decreased 5-hmC levels are an epigenetic hallmark for malignancy and tumor progression in HGSOC. In addition, global 5-hmC loss is associated with a decreased response to platinum-based chemotherapy, shorter time to relapse, and poor overall survival in patients newly diagnosed with HGSOC. Interestingly, the rescue of 5-hmC loss restores sensitivity to platinum chemotherapy in vitro and in vivo, decreases the percentage of tumor cells with cancer stem cell markers, and increases overall survival in an aggressive animal model of platinum-resistant disease. Conclusions: Consequently, a global analysis of patient 5-hmC levels should be included in future clinical trials, which use pretreatment with epigenetic adjuvants to elevate 5-hmC levels and improve the efficacy of current chemotherapies. Identifying prognostic epigenetic markers and altering chemotherapeutic regimens to incorporate DNMTi pretreatment in tumors with low 5-hmC levels could have important clinical implications for newly diagnosed HGSOC disease. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | AMER ASSOC CANCER RESEARCH | - |
dc.title | Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Ko, Joo Yeon | - |
dc.identifier.doi | 10.1158/1078-0432.CCR-17-1958 | - |
dc.identifier.scopusid | 2-s2.0-85047529022 | - |
dc.identifier.wosid | 000427627400017 | - |
dc.identifier.bibliographicCitation | CLINICAL CANCER RESEARCH, v.24, no.6, pp.1389 - 1401 | - |
dc.relation.isPartOf | CLINICAL CANCER RESEARCH | - |
dc.citation.title | CLINICAL CANCER RESEARCH | - |
dc.citation.volume | 24 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1389 | - |
dc.citation.endPage | 1401 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | CONVENTIONAL CARE REGIMENS | - |
dc.subject.keywordPlus | STEM-CELLS | - |
dc.subject.keywordPlus | ALDEHYDE DEHYDROGENASE | - |
dc.subject.keywordPlus | DNA METHYLATION | - |
dc.subject.keywordPlus | PROMOTER HYPERMETHYLATION | - |
dc.subject.keywordPlus | SPORADIC BREAST | - |
dc.subject.keywordPlus | BRCA1 | - |
dc.subject.keywordPlus | PLATINUM | - |
dc.subject.keywordPlus | TET2 | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.identifier.url | https://clincancerres.aacrjournals.org/content/24/6/1389 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.